Journal
AUTOPHAGY
Volume -, Issue -, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/15548627.2023.2241125
Keywords
Autophagy; collagen VI; nutraceutical; skeletal muscle; spermidine; >
Categories
Ask authors/readers for more resources
COL6-related myopathies (COL6-RM) are inherited muscle disorders caused by mutations of COL6 genes, characterized by early-onset muscle weakness. Targeting autophagy through dietary spermidine administration has shown beneficial effects in col6a1(-/-) mice and COL6-RM patients. A 100-day-long spermidine regimen rescues muscle strength in col6a1(-/-) mice and improves mitochondria and neuromuscular junction integrity, suggesting its potential application in clinical trials for COL6-RM.
COL6 (collagen type VI)-related myopathies (COL6-RM) are a distinct group of inherited muscle disorders caused by mutations of COL6 genes and characterized by early-onset muscle weakness, for which no cure is available yet. Key pathophysiological features of COL6-deficient muscles involve impaired macroautophagy/autophagy, mitochondrial dysfunction, neuromuscular junction fragmentation and myofiber apoptosis. Targeting autophagy by dietary means elicited beneficial effects in both col6a1 null (col6a1(-/-)) mice and COL6-RM patients. We previously demonstrated that one-month per os administration of the nutraceutical spermidine reactivates autophagy and ameliorates myofiber defects in col6a1(-/-) mice but does not elicit functional improvement. Here we show that a 100-day-long spermidine regimen is able to rescue muscle strength in col6a1(-/-) mice, with also a beneficial impact on mitochondria and neuromuscular junction integrity, without any noticeable side effects. Altogether, these data provide a rationale for the application of spermidine in prospective clinical trials for COL6-RM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available